![Marc Augustin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermogen: 121 264 $ op 31-05-2026
Marc Augustin currently works at PolyPeptide Group AG, as Chief Financial Officer from 2024.
Mr. Augustin also formerly worked at Lonza AG, as Vice President-Finance and Smith & Nephew Schweiz AG, as Head-Finance from 2009 to 2016.
Mr. Augustin received his undergraduate degree from Heinrich-Heine-Universität Düsseldorf.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
POLYPEPTIDE GROUP AG 0,01% | 31-12-2025 | 2.500 ( 0,01% ) | 121 264 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| POLYPEPTIDE GROUP AG | Financieel Directeur/CFO | 02-01-2024 |
| Bedrijven | Functie | Einde |
|---|---|---|
Smith & Nephew Schweiz AG | Corporate Officer/Principal | 01-01-2016 |
Lonza AG
 Lonza AG BiotechnologyHealth Technology Engages in developing, producing and selling pharmaceutical and chemical products | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
| Bedrijven in privébezit | 4 |
|---|---|
Heinrich-Heine-Universität Düsseldorf
 Heinrich-Heine-Universität Düsseldorf Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lonza AG
Lonza AG BiotechnologyHealth Technology Engages in developing, producing and selling pharmaceutical and chemical products | Health Technology |
Smith & Nephew Schweiz AG | |
PolyPeptide Group AG
 PolyPeptide Group AG BiotechnologyHealth Technology Manufactures polypeptide and custom peptide synthesis | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau
